Vozmozhnosti ispol'zovaniya mukoliticheskoy terapii
- Autores: Tarasova G.D1
-
Afiliações:
- Edição: Nº 14 (2015)
- Páginas: 72-77
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288154
- ID: 288154
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The study was aimed to the evaluation of the efficiency of the drug Fluditec in the complex treatment of inflammatory diseases of the upper respiratory tract. The study included 58 sickly children aged from 3 to 8 years. After a course of treatment, exfoliative cytograms were assessed. In 64.7% of the children in the study group, results of cytograms indicated the regulation of process of phagocytosis and the absence of exudation suppression while reducing the number of microorganisms. In the control group, similar changes have occurred only in 36.4% of patients, and were less pronounced. The results show the effectiveness of the use of the drug Fluditec in the complex treatment of inflammatory diseases of the upper respiratory tract, as well as the rationality of its inclusion in the complex treatment of children during sanatorium stage of rehabilitation.
Palavras-chave
Texto integral
Bibliografia
- Зайцева О.В. Лечение кашля у детей и подростков: рациональный выбор. Consilium-medicum. 2003;5(4):204-7.
- Мизерницкий Ю.Л., Мельникова И.М. Муколитическая и отхаркивающая фармакотерапия при заболеваниях легких у детей. М., 2013. 120 с.
- Рязанцев С.В. Роль муколитических, секретолитических и секретомоторных препаратов в лечении острых и хронических синуситов у детей. Новости оторинолар. и логопатол. 2002;1(29):129-32.
- Самсыгина Г.А., Зайцева О.В. Бронхиты у детей. Отхаркиывающая и муколитическая терапия. Пособие для врачей. М., 1999. 36 с.
- Тарасова Г.Д. Клиника и лечение иммунопрепаратами гайморита у детей. Дисс. канд. мед. наук. М., 1983. 21 с.
- Chalumeau M.,Cheron G.,Assathiany R., Moulin F., Bavoux F., Breart G., Pons G. Mucolitic agents for acute respiratory tract infections in infants: a pharmaco-epiderniologic problem? Arch. Pediatr. 2002;9:1128-36.
- Commins D.J., Koay B.C., Bates G.J.B., Moore R.A., Sleeman K., Mitchell B., Bates S. The role of Mucodyne in reducing the need for surgery in patients with persistent otitis media with effusion. Clin. Otolaryngol. 2000, 25:274-49. приема. Поэтому не требуется дополнительной мукоактивной терапии.
- Maccio Y., Madeddu C., Panzone F., Mantovani G. Carbocystein: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin. Pharmacother. 2009;10(4):693-703.
- Mallet P., Moudi N., Dubus J.C. et al., Respiratory paradoxical adverse drug reactions associated with acetylcysteine and carbocysteine systemic use in paediatric patients:a national survey. Plos One. 2011;6(7):E22792.
- Moore R.A., Commins D., Bates G., Phillips C.J. 2S-carboxymethylcysteine in the treatment of glue ear: quantitative systematic review. BMC Family Practice. 2001;2:3.
Arquivos suplementares
